AWARD NUMBER: W81XWH-16-1-0704

TITLE: Physical Telerehabilitation in Patients with Multiple Sclerosis with Significant Mobility Impairment

PRINCIPAL INVESTIGATOR: Joel Stein, MD

CONTRACTING ORGANIZATION: Columbia University Medical Center

REPORT DATE: Oct 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
October 2019	Annual	30 Sep 2018 – 29 Sep 2019

4. TITLE AND SUBTITLE

Physical Telerehabilitation in Patients with Multiple Sclerosis with Significant Mobility Impairment

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-16-1-0704

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Joseph Finkelstein, MD, PhD

E-Mail: jf193@columbia.edu

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

TRUSTEES OF COLUMBIA UNIVERSITY
630 W 168TH ST FL 4
NEW YORK NY 10032

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
Purpose: The clinical benefits of physical rehabilitation in patients with multiple sclerosis with significant mobility impairment (PwMSMI) have been well documented. However multiple barriers limit ability of these patients to continuously participate in rehabilitation programs. The purpose of this project is to conduct a pilot clinical trial aimed at establishing the extent of impact of the proposed patient-centered physical telerehabilitation model on functional and symptom outcomes in PwMSMI. Scope: This report covers activities carried out during the Year 2 of the project. The major tasks during the reporting period comprised Task 2 (Identify and Enroll Eligible Study Subjects during Months 7-27); and Task 3 (Conduct Randomized Controlled Trial during Months 7-27). Major findings: The Task 2 was successfully completed. The Task 3 has been implemented as planned. Overall, 91 potentially eligible patients were recruited, 74 patients were screened, and 58 patients were consented and enrolled into the study.

15. SUBJECT TERMS
rehabilitation, multiple sclerosis, mobility impairment, telemedicine

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	6	19b. TELEPHONE NUMBER *(include area code)*

TABLE OF CONTENTS

Page

1. **INTRODUCTION:** *Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.*

The clinical benefits of physical rehabilitation in patients with multiple sclerosis with significant mobility impairment (PwMSMI) have been well documented. Life-long engagement in physical rehabilitation is required in these patients to reduce functional decline. However multiple barriers limit ability of these patients to continuously participate in rehabilitation programs. Telemedicine approaches have potential to significantly improve access of PwMSMI to rehabilitation services but their efficacy has not been evaluated systematically. The purpose of this project is to conduct a pilot clinical trial aimed at establishing the extent of impact of the proposed patient-centered physical telerehabilitation model on functional and symptom outcomes in PwMSMI. The scope of work includes enrollment of 58 PwMSMI in a pilot randomized controlled trial and data analysis.

2. **KEYWORDS:** *Provide a brief list of keywords (limit to 20 words).*

Multiple Sclerosis, Rehabilitation, Mobility Impairment, Telemedicine

3. **ACCOMPLISHMENTS:** *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

The major goal of the project is to determine the effect of physical telerehabilitation on functional outcomes in PwMSMI with significant mobility impairment in a pilot randomized controlled trial. This report covers activities carried out during the Year 3 of the project. The major tasks during the reporting period comprised Task 3 (Conduct Randomized Controlled Trial during Months 7-33), and Task 4 (Data Analysis during Months 7-36).

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

The major activities comprised (1) completion of patient follow-up; (2) data entry and analysis. Specific objectives included maintaining data infrastructure, data management, performing statistical analysis according to specifications, working on dissemination of findings.

The descriptive analysis demonstrated that there was no difference in major patient characteristics between the control (C) and intervention (I) groups: Age (C: 54±12, I: 55±12), Years with MS (C: 19±13, I: 20±12), Years of education (C: 15±3, I: 15±3), Annual relapse number (C: 0.6±1.42, I: 0.7±1.96), ER visits in the last 3 months at the baseline (C: 0.2±0.43, I: 0.3±0.58). There was no difference between the study groups (C vs. I) in the distribution of the following sociodemographic parameters: Gender (C: 73-27, I: 77-23, F-M), Ethnicity (C: 14-86, I: 12-88, Hispanic: yes-no), Born in US (C: 18-82, I: 21-79, no-yes), Internet use (C: 87-13, I: 84-16, once a day vs. less than once a day). Baseline characteristics of mobility, balance and spasticity in the study groups did not differ at baseline including Multiple Sclerosis Impact Scale (MSIS), Modified Ashworth Scale (MAS), Berg Balance Scale (BBS), Modified Fatigue Impact Scale (MFIS), and Multiple Sclerosis Impact Scale (MSIS-29).

A comparison of functional outcomes at baseline and 3-month using paired t-test identified statistically significant improvement only in the intervention group whereas changes in the control group did not reach statistical significance. Patients in the intervention group demonstrated statistically significant positive changes in MSIS (t=2.714, p=0.013), MAS (t=2.760, p=0.015), MFIS (t=2.877, p= 0.041) and BBS (t=2.950, p=0.021). In addition, at 6-month, the intervention group demonstrated statistically significant decrease in urgent care utilization. No significant differences were found in these parameters in the control group.

What opportunities for training and professional development has the project provided?
If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. "Training" activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. "Professional development" activities result in increased knowledge or skill in one's area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Good Clinical Practice (GCP) training has been completed by all project members.

How were the results disseminated to communities of interest?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

The results of this project were presented at the:
1) 7th International Conference on the Global Telehealth (GT2018) conducted by the International Medical Informatics Association (IMIA);
2) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020;
3) American Medical Informatics Association (AMIA) 2020 Summit

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

We will continue with on-going analysis of collected data and prepare manuscripts for conference presentations and publication in peer-reviewed journals. Following preliminary descriptive analysis, we will examine bivariate associations using cross-tabulations and scatter-plots. We will use chi-square tests for assessing crude associations between two categorical variables, t tests for comparing two group means, and correlation coefficients for crude relationships between two continuous variables. Specifically, we will assess whether the two study groups are comparable in terms of baseline covariates by t tests or chi-square tests and whether change in functional and psycho-social variables is significantly different between control and telerehabilitation groups. As a secondary analysis, we will analyze temporal trends in both groups and perform explanatory analysis that examines the effect of the intervention after adjusting for potential confounders and effect modifiers. We will also analyze the system usage logs to assess association between the system usage patterns and the study outcomes. The study results will be used for manuscript submission and for preparation of a multi-center grant application to further elucidate clinical impact of home-based telerehabilitation in multiple sclerosis.

4. **IMPACT:** D*escribe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

What was the impact on the development of the principal discipline(s) of the project?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Given the greater mobility disability and greater difficulty with transport that is typically seen in PwMSMI, this home-based telerehabilitation program is expected to have the greatest impact on this group of individuals. The proposed pilot clinical trial will have a major impact on multiple sclerosis treatment by providing evidence on feasibility and clinical impact of innovative model of home-based rehabilitation in PwMSMI.

What was the impact on other disciplines?
If there is nothing significant to report during this reporting period, state "Nothing to Report." Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

The demonstration of high acceptance of telerehabilitation by patients with multiple sclerosis with severe mobility impairment and evidence of positive impact of telerehabilitation on patient symptomatology has relevance to other neurodegenerative diseases. Our findings pave the way for development and implementation of effective home-based telerehabilitation approaches for patients with a spectrum of neurodegenerative conditions, older adults and individuals with limited mobility.

What was the impact on technology transfer?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to Report.

What was the impact on society beyond science and technology?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

The results from this project are likely to make a significant impact on modern approaches for providing rehabilitation services to people with significant mobility impairment. This project paves way for utilizing information technology to improve functional status and quality of life for people who has mobility disability and limited access to life-long rehabilitation services.

5. **CHANGES/PROBLEMS:** *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*

Changes in approach and reasons for change
Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

Nothing to Report.

Actual or anticipated problems or delays and actions or plans to resolve them
Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

The change of Principal Investigator at Columbia University in the second year of the study due to the move of the initial Principal Investigator to the Icahn School of Medicine at Mount Sinai resulted in a necessity to revise original timeline and scope work. This process was time-consuming and resulted in a later than anticipated start of data analysis procedures.

Changes that had a significant impact on expenditures
Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to Report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents
Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

Nothing to Report.

Significant changes in use or care of vertebrate animals

Nothing to Report.

Significant changes in use of biohazards and/or select agents

Nothing to Report.

6. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*

- **Publications, conference papers, and presentations**
  Report only the major publication(s) resulting from the work under this award.

  Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Jeong IC, Liu J, Finkelstein J. Association between System Usage Pattern and Impact of Web-Based Telerehabilitation in Patients with Multiple Sclerosis. Accepted for presentation at the American Medical Informatics Association (AMIA) 2020 Summit, March 23-26, 2020, TX.

Jeong IC, Karpatkin H, Stein J, Finkelstein J. Relationship between Exercise Duration in Multimodal Telerehabilitation and Quality of Sleep in Patients with Multiple Sclerosis. Stud Health Technol Inform. 2020, in press.

Finkelstein J, Jeong IC, Karpatkin H. Physical Telerehabilitation Ameliorates Impact of Multiple Sclerosis in a Randomized Control Trial. Accepted for presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, February 27-29, 2020, FL.

Jeong IC, Karpatkin H, Finkelstein J. Physical Telerehabilitation Improves Quality of Life in Patients with Multiple Sclerosis. Submitted to Stud Health Technol Inform.

Jeong IC, Liu J, Finkelstein J. Factors Affecting Adherence with Telerehabilitation in Patients with Multiple Sclerosis. Stud Health Technol Inform. 2019;257:189-193. PMID: 30741194

Finkelstein J, Liu J. Usability of Telerehabilitation System Supporting Multipronged Exercise in Patients with Multiple Sclerosis. Stud Health Technol Inform. 2018;251:281-284. PMID: 29968658

Finkelstein J, Liu J. Designing Telerehabilitation System for Multipronged Exercise in Patients with Multiple Sclerosis. Stud Health Technol Inform. 2018;254:16-23. PMID: 30306953

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to Report.

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Nothing to Report.

- **Website(s) or other Internet site(s)**
List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report.

- **Technologies or techniques**
Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to Report.

- **Inventions, patent applications, and/or licenses**
Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report.

- **Other Products**

  Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

  - *data or databases;*
  - *physical collections;*
  - *audio or video products;*
  - *software;*
  - *models;*
  - *educational aids or curricula;*
  - *instruments or equipment;*
  - *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
  - *clinical interventions;*
  - *new business creation; and*
  - *other.*

Nothing to Report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change".

Example:

Name:	*Mary Smith*
Project Role:	*Graduate Student*
Researcher Identifier (e.g. ORCID ID):	*1234567*
Nearest person month worked:	*5*
Contribution to Project:	*Ms. Smith has performed work in the area of combined error-control and constrained coding.*
Funding Support:	*The Ford Foundation (Complete only if the funding support is provided from other than this award.)*

Name: Dr. Joel Stein
Project Role: PI
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 1 calendar months
Contribution to Project: Dr. Stein is the PI to oversee the overall project.

Name: Nancy Lee
Project Role: Research Coordinator
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 1 calendar months
Contribution to Project: Ms. Lee works with PI on submitting IRB protocols and developing the study manual, and oversee patient enrollment and follow-up on a daily basis.

Name: Margaret O'Neil
Project Role: Physical Therapist
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 1 calendar months
Contribution to Project: Dr. O'Neil oversees the exercise program design and implementation, and trouble-shoots any participant difficulty in participation related to physical function.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to Report.

What other organizations were involved as partners?
If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:
Organization Name:
Location of Organization: (if foreign location list country)
Partner's contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner's facilities for project activities);*
- *Collaboration (e.g., partner's staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner's staff use each other's facilities, work at each other's site); and*
- *Other.*

Organization Name: Icahn School of Medicine at Mount Sinai
Location of Organization: 1425 Madison Ave, New York, NY 10029
Partner's contribution to the project: Subcontract to complete the Tasks #3 and 4 of the project.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to* ***https://ers.amedd.army.mil*** *for each unique award.*

QUAD CHARTS: *If applicable, the Quad Chart (available on https://www.usamraa.army.mil) should be updated and submitted with attachments.*

9. APPENDICES: *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*

Alvarez, Ana J.

From: Alvarez, Ana J.
Sent: Wednesday, March 11, 2020 10:09 AM
To: usarmy.detrick.medcom-usamrmc.mbx.egs-no-reply@mail.mil; anna.e.tschiffely.ctr@mail.mil; meropi.athanasiou.civ@mail.mil; mark.d.wilkison.civ@mail.mil
Cc: Stein, Joel; Iyer, Krishnakumar S.; Finkelstein, Joseph; Amescua, Amanda; Santos, Milerva (MSH); Berrios, Edwin
Subject: RE: PAST DUE - Technical Report for DoD Award W81XWH-16-1-0704,MS150167
Attachments: W81XWH-16-1-0704_Annual Technical Report_Joel Stein.pdf; Re: [Non-DoD Source] RE: Reminder- Technical Report Due Date Approaching for DoD Award W81XWH-16-1-0704, MS150167

Good Morning,

As a follow up to the email below, attached is the annual technical report for Dr. Joel Stein's award: W81XWH-16-1-0704.

I would like to request access to this award via eBRAP in order to submit the report electronically. Please find attached Dr. Stein's email confirming my role for this grant as a Business Official.

Thank you,

Ana J. Alvarez
Senior Project Officer
Columbia University Irving Medical Center
Sponsored Projects Administration
(212) 342-0266
aa461@columbia.edu

From: Amescua, Amanda <amanda.amescua@mssm.edu>
Sent: Wednesday, March 4, 2020 9:26 AM
To: usarmy.detrick.medcom-usamrmc.mbx.egs-no-reply@mail.mil; Stein, Joel <js1165@cumc.columbia.edu>; Finkelstein, Joseph <Joseph.Finkelstein@mssm.edu>; Santos, Milerva (MSH) <milerva.santos@mountsinai.org>; grants-office <grants-office@columbia.edu>
Cc: anna.e.tschiffely.ctr@mail.mil; meropi.athanasiou.civ@mail.mil; mark.d.wilkison.civ@mail.mil; Berrios, Edwin <edwin.berrios@mssm.edu>; Iyer, Krishnakumar S. <ksi2101@cumc.columbia.edu>
Subject: RE: PAST DUE - Technical Report for DoD Award W81XWH-16-1-0704,MS150167
Importance: High

Good Morning,

I am including the prime grant recipient organization, Columbia University, on this email exchange.

Drs. Stein and Finkelstein, please advise if you need additional assistance to submit the required, overdue Technical Report. Please also note highlighted portion from email below. Your prompt attention to this issue is appreciated.

Thanks,

Amanda Amescua, CRA

Director, AOR
Grants and Contracts Office
Icahn School of Medicine at Mount Sinai
(646) 605-8659

From: usarmy.detrick.medcom-usamrmc.mbx.egs-no-reply@mail.mil <usarmy.detrick.medcom-usamrmc.mbx.egs-no-reply@mail.mil>
Sent: Tuesday, March 3, 2020 8:48 PM
To: js1165@cumc.columbia.edu
Cc: anna.e.tschiffely.ctr@mail.mil; meropi.athanasiou.civ@mail.mil; Amescua, Amanda <amanda.amescua@mssm.edu>; mark.d.wilkison.civ@mail.mil
Subject: PAST DUE - Technical Report for DoD Award W81XWH-16-1-0704,MS150167

USE CAUTION: External Message.

Log Number: MS150167
Award Number: W81XWH-16-1-0704
Award PI: Joel Stein
Report Type: Final
Report Due Date: 01/27/2020
Science Officer: Dr. Anna Tschiffely
Science Officer Email: anna.e.tschiffely.ctr@mail.mil

This office still has not received your Final report for the subject award.
Your report was due in our office no later than 01/27/2020 and is now past due.
Complete, accurate and timely submission of reports on the progress and/or finding of the research are required in accordance with the basic agreement.
Failure to meet the reporting requirements of your agreement with this Command may result in a recommendation to reconsider funding for future awards with your organization. To avoid such action, you should take immediate action to complete your report.

If you have already submitted the required report, please disregard this message. Please see important process updates below.

SUBMISSION INSTRUCTIONS:
To obtain a copy of the format requirements and to view a sample cover page, Standard Form 298 and table of contents, click on "Technical Reporting Requirements" at the U.S. Army Medical Research and Development Command website at
https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting.

*** IMPORTANT ***

When you are formatting your report you are given the option to select between:

An UNLIMITED distribution designation which will become accessible to the general public through the Defense Technical Information Center (DTIC) data repository at https://discover.dtic.mil/

OR

A LIMITED distribution designation which will allow restricted access to U.S. Government agencies only; reports containing unpublished, patentable, or proprietary information that are not ready for public release should be given the LIMITED distribution designation.

If you have questions or would like further clarification please contact your assigned science officer.

*** NEW PROCESS***
Starting October 1, 2019 USA MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA) began transitioning all Technical Report submissions to a new system the Electronic Biomedical Research Application Portal (eBRAP) https://ebrap.org

For Annual and Final Reports, if you attempt to access the old submission site stated in your award, you will be redirected to https://ebrap.org
Annual/Final Reports emailed will not be accepted.

For Monthly/Quarterly/Semi-Annual reports currently submitted via email to the GOR/COR and GS/CS, we will continue accepting the reports for a period of up to 6 months by email, at which point all reports must be submitted to https://ebrap.org . However, you are encouraged to use the new site now.

Most investigators already have an eBRAP account; if so please login and navigate to the Technical Reports Tab under "Award Management" to submit your reports. If you forgot your password, please click on "Forgot your Password?" on the homepage and follow instructions; do not register/start a new account.

If you are new to eBRAP, please register using the Start Registration button on the homepage.

If there was a PI or Institutional transfer of the original award and you do not see the award after you login please contact the eBRAP help desk (Help@eBRAP.org).

This is an automated message on behalf of:
Office of the Deputy Chief of Staff for Information Management (DCSIM),
U.S. Army Medical Research and Development Command (USAMRDC),
Fort Detrick, MD 21702-5012

E-mail Contact: usarmy.detrick.medcom-usamrmc.mbx.usamrmc-rmi-s@mail.mil

Alvarez, Ana J.

From: Stein, Joel
Sent: Wednesday, March 4, 2020 10:15 AM
To: Alvarez, Ana J.; Tschiffely, Anna E CTR USARMY MEDCOM CDMRP (USA); Athanasiou, Meropi CIV USARMY MEDCOM CDMRP (USA); Wilkison, Mark D CIV USARMY MEDCOM USAMRAA (USA)
Subject: Re: [Non-DoD Source] RE: Reminder- Technical Report Due Date Approaching for DoD Award W81XWH-16-1-0704, MS150167

Follow Up Flag: Follow up
Flag Status: Completed

This is confirmation of Ms. Ana Alvarez's role as the Business Official for this grant.

Thank you

Joel Stein, MD

Simon Baruch Professor and Chair
Department of Rehabilitation and Regenerative Medicine Columbia University Vagelos College of Physicians and Surgeons

Professor and Chair
Department of Rehabilitation Medicine
Weill Cornell Medicine

Physiatrist-in-Chief
NewYork-Presbyterian Hospital

180 Ft. Washington Ave.
Harkness Pavilion Room 1-165
New York, NY 10032

Ph: (212) 305-4818
Fax: (212) 342-3138

Email: js1165@columbia.edu
Jos7021@med.cornell.edu
--

On 3/4/20, 10:05 AM, "Alvarez, Ana J." <aa461@cumc.columbia.edu> wrote:

Good morning Dr. Stein,

In order to submit the your progress report via the eBRAP system as requested below, the sponsor (copied above) will need you to confirm my role as the Business Official.

Thank you,

Ana J. Alvarez
Senior Project Officer
Columbia University Irving Medical Center
Sponsored Projects Administration
(212) 342-0266
aa461@columbia.edu
-----Original Message-----
From: Tschiffely, Anna E CTR USARMY MEDCOM CDMRP (USA) <anna.e.tschiffely.ctr@mail.mil>
Sent: Friday, January 24, 2020 9:59 AM
To: Alvarez, Ana J. <aa461@cumc.columbia.edu>; Athanasiou, Meropi CIV USARMY MEDCOM CDMRP (USA) <meropi.athanasiou.civ@mail.mil>; Wilkison, Mark D CIV USARMY MEDCOM USAMRAA (USA) <mark.d.wilkison.civ@mail.mil>
Cc: Stein, Joel <js1165@cumc.columbia.edu>
Subject: RE: [Non-DoD Source] RE: Reminder- Technical Report Due Date Approaching for DoD Award W81XWH-16-1-0704, MS150167

Good Morning,
Thank you for this report.
All technical reports should be submitted via the eBRAP portal.
Please see information below and let me now if you have any questions.

*** IMPORTANT ***

When you are formatting your report you are given the option to select between:

An UNLIMITED distribution designation which will become accessible to the general public through the Defense Technical Information Center (DTIC) data repository at https://urldefense.proofpoint.com/v2/url?u=https-3A__discover.dtic.mil_&d=DwIGaQ&c=G2MiLlal7SXE3PeSnG8W6_JBU6FcdVjSsBSbw6gcR0U&r=Mrqgix0ehjAiDpnJZoiaYNhFHlNvZMZ7-9N3bmYVA6g&m=1k7uQfAhhiVshgCBExT5T0UXozUYnmJCNKbAxptG6yM&s=dlGN2YhiboERO0lIv9vwaPcVDyt_22uYO0ZqCxegEfE&e=

OR

A LIMITED distribution designation which will allow restricted access to U.S. Government agencies only; reports containing unpublished, patentable, or proprietary information that are not ready for public release should be given the LIMITED distribution designation.

If you have questions or would like further clarification please contact your assigned science officer.

*** NEW PROCESS***
Starting October 1, 2019 USA MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA) began transitioning all Technical Report submissions to a new system the Electronic Biomedical Research Application Portal (eBRAP) https://urldefense.proofpoint.com/v2/url?u=https-3A__ebrap.org&d=DwIGaQ&c=G2MiLlal7SXE3PeSnG8W6_JBU6FcdVjSsBSbw6gcR0U&r=Mrqgix0ehjAi